枳术宽中胶囊联合维酶素片治疗慢性萎缩性胃炎的临床研究  

Clinical study on Zhizhu Kuanzhong Capsules combined with Vitacoenzyme Tablets in treatment of chronic atrophic gastritis

作　　者：项红霞 王岩 冷静 孟欣 祁志强 田野[3] XIANG Hong-xia;WANG Yan;LENG Jing;MENG Xin;QI Zhi-qiang;TIAN Ye(Department of Surgery,Nankai University Affiliated Hospital(Tianjin Fourth Hospital),Tianjin 300222,China;Department of Gastroenterology,Nankai University Affiliated Hospital(Tianjin Fourth Hospital),Tianjin 300222,China;Department of Internal Medicine,General Hospital of Tianjin Medical University,Tianjin 300052,China)

机构地区：[1]南开大学附属医院(天津市第四医院)外科,天津300222 [2]南开大学附属医院(天津市第四医院)消化内科,天津300222 [3]天津医科大学总医院内科,天津300052

出　　处：《现代药物与临床》2020年第4期668-672,共5页Drugs & Clinic

基　　金：天津市科技计划项目(16JCQNJC10600)。

摘　　要：目的探讨枳术宽中胶囊联合维酶素片治疗慢性萎缩性胃炎的临床疗效。方法选取2017年1月-2019年12月南开大学附属医院消化内科收治的126例慢性萎缩性胃炎患者作为实验对象,按照随机数字表法将126例患者分为两组,每组各有63例。对照组口服维酶素片,1.2 g/次,3次/d。治疗组在对照组基础上口服枳术宽中胶囊,3粒/次,3次/d。两组患者连续治疗4周。观察两组的临床疗效,比较两组病理学指标慢性炎症程度、活动性、萎缩度、肠化生、幽门螺杆菌(HP)感染、胃黏膜炎症因子C-反应蛋白(CRP)、前列腺素E2(PGE2)、白细胞介素-1β(IL-1β)、肿瘤坏死因子-α(TNF-α)。结果治疗后,治疗组的总有效率(92.06%)比对照组高(79.37%),差异有统计学意义(P<0.05)。治疗后,两组的慢性炎症程度、活动性、萎缩度、肠化生、HP感染评分明显减轻(P<0.05),且治疗组较对照组减轻的更明显,差异有统计学意义(P<0.05)。治疗后,两组胃黏膜的CRP、IL-1β、TNF-α明显低于治疗前,PGE2明显高于治疗前(P<0.05);治疗组治疗后胃黏膜的CRP、IL-1β、TNF-α低于对照组,PGE2比对照组高(P<0.05)。结论枳术宽中胶囊联合维酶素片治疗慢性萎缩性胃炎具有较好的疗效,能减轻胃黏膜症状,降低炎症反应,具有较好的临床研究价值。Objective To explore the clinical effect of Zhizhu Kuanzhong Capsules combined with Vitacoenzyme Tablets in treatment of chronic atrophic gastritis. Methods Patients(126 cases) with chronic atrophic gastritis in Nankai University Affiliated Hospital from January 2017 to December 2019 were randomly divided into control and treatment groups, and each group had 63 cases. Patients in the control group were po administered with Vitacoenzyme Tablets, 1.2 g/time, three times daily. Patients in the treatment group were po administered with Zhizhu Kuanzhong Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and pathological indexes, such as chronic inflammation, activity, atrophy, intestinal metaplasia, Helicobacter pylori(HP) infection, and inflammatory factors of gastric mucosa, such as CRP, PGE2, IL-1β, TNF-α in two groups were compared. Results After treatment, the clinical efficacies in the treatment group(92.06%) was higher than that in the control group(79.37%), and the difference was statistically significant(P < 0.05). After treatment, chronic inflammation, activity, atrophy, intestinal metaplasia and HP infection scores in two groups were significantly decreased(P < 0.05), and the scores in the treatment group were significantly better than those in the control group, and the difference was statistically significant(P < 0.05). After treatment, the levels of CRP, IL-1β, and TNF-α in two groups were significantly decreased, but the levels of PGE2 in two groups were significantly increased(P < 0.05), the difference was statistically significant(P < 0.05). After treatment, the levels of CRP, IL-1β, and TNF-α in the treatment group were lower than those in the control group, but the level of PGE2 in the treatment group was higher than that in the control group, with significant difference between two groups(P < 0.05). Conclusion Zhizhu Kuanzhong Capsules combined with Vitacoenzyme

关 键 词：枳术宽中胶囊 维酶素片 慢性萎缩性胃炎 病理学指标 炎症因子 C-反应蛋白 前列腺素E2 

分 类 号：R975[医药卫生—药品]